Rakici Halil, Ayaz Teslime, Akdogan Remzi Adnan, Bedir Recep
Department of Gastroenterology, Recep Tayyip Erdogan University, School of Medicine, Rize, Turkey.
Digestion. 2014;90(4):261-4. doi: 10.1159/000369788. Epub 2014 Dec 24.
It is recommended that treatments that include clarithromycin should be avoided in eradication of Helicobacter pylori (HP) in cases where clarithromycin resistance is higher than 20%. We aimed to compare levofloxacin- and moxifloxacin-based triple therapies with standard treatment and with each other in eradication of helicobacter pylori as first-line therapy.
Patients were randomized prospectively as three groups. There were 102 patients in the levofloxacin group, 101 patients in the moxifloxacin group, and 103 patients in the standard treatment group. The patients received levofloxacin 500 mg daily, amoxicillin 1 g b.i.d. and lansoprazole 30 mg b.i.d. for ten days (LAL) in the levofloxacin group; moxifloxacin 400 mg daily, amoxicillin 1 g b.i.d. and lansoprazole 30 mg b.i.d. (MAL) in the moxifloxacin group; and clarithromycin 500 mg b.i.d., amoxicillin 1 g b.i.d. and lansoprazole 30 mg b.i.d. (CAL) in the standard treatment group. At post-treatment week 6, HP was checked by using stool antigen test.
In the eradication of Helicobacter pylori, the success rate as determined by per protocol (PP) analysis was 92% in the LAL group, 91.8% in the MAL group, and 82.4% in the CAL group. A statistically significant difference was found in the LAL and MAL groups compared to the CAL group (p < 0.05). There was no difference between the LAL and MAL groups.
It was determined that levofloxacin- and moxifloxacin-based triple therapies were more effective than the standard treatment in first-line setting in the eradication of Helicobacter pylori. In addition, no difference was found between levofloxacin- and moxifloxacin-based triple therapies. Currently observed high efficacy may be evaluated in treatment. Although quinolon resistance is not considered a major problem, it appears to be a factor that may reduce treatment success over a period of time.
对于克拉霉素耐药率高于20%的幽门螺杆菌(HP)根除病例,建议避免使用含克拉霉素的治疗方案。我们旨在比较以左氧氟沙星和莫西沙星为基础的三联疗法与标准治疗方案在作为一线治疗根除幽门螺杆菌方面的疗效,以及这两种疗法之间的疗效差异。
前瞻性地将患者随机分为三组。左氧氟沙星组102例患者,莫西沙星组101例患者,标准治疗组103例患者。左氧氟沙星组患者接受每日500毫克左氧氟沙星、每日两次1克阿莫西林和每日两次30毫克兰索拉唑,疗程10天(LAL);莫西沙星组患者接受每日400毫克莫西沙星、每日两次1克阿莫西林和每日两次30毫克兰索拉唑(MAL);标准治疗组患者接受每日两次500毫克克拉霉素、每日两次1克阿莫西林和每日两次30毫克兰索拉唑(CAL)。治疗后第6周,采用粪便抗原检测法检测幽门螺杆菌。
在幽门螺杆菌根除方面,按符合方案(PP)分析确定的成功率,LAL组为92%,MAL组为91.8%,CAL组为82.4%。与CAL组相比,LAL组和MAL组有统计学显著差异(p < 0.05)。LAL组和MAL组之间无差异。
已确定以左氧氟沙星和莫西沙星为基础的三联疗法在一线治疗中根除幽门螺杆菌比标准治疗更有效。此外,以左氧氟沙星和莫西沙星为基础的三联疗法之间未发现差异。目前观察到的高疗效可在治疗中进行评估。虽然喹诺酮耐药性不被视为主要问题,但似乎是一个可能在一段时间内降低治疗成功率的因素。